Johnson & johnson has a cornucopia of health care goods, from household items like Band-Aids and Tylenol to drugs like Procrit and Risperdal. Still, Wall Street worries its pipeline is weak.Not to worry, says Kurt H. Kruger, an analyst with Bane of America Securities. He sees a blockbuster coming: an improvement on an artery-opening device called a stent—J&J (NYSE: JNJ) debuted the original in 1996. In 25% of cases arteries respond by growing scar tissue around the stent, narrowing the passage again. To fight that, J&J has developed a stent coated with a drug to inhibit cell growth.
展开▼
机译：强生（Johnson＆johnson）拥有大量保健品，从诸如创可贴和泰诺醇之类的家居用品到诸如Procrit和Risperdal之类的药品。美银证券（Bane of America Securities）分析师库特·克鲁格（Kurt H.他看到了一个惊人的突破：一种称为支架的动脉张开装置的改进—强生公司（NYSE：JNJ）于1996年推出了该产品。在25％的情况下，动脉的反应是在支架周围生长疤痕组织，从而再次缩小了通道。为了解决这个问题，强生公司开发了一种覆有药物的支架，以抑制细胞生长。
展开▼
